A systemic gentamicin pathway across the stria vascularis

Chun Fu Dai, Peter Steyger

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

The mechanism(s) by which systemically-administered aminoglycosides enter the cochlea remain poorly understood. To elucidate which mechanisms may be involved, we co-administered different molar ratios of gentamicin and fluorescent gentamicin (GTTR) to mice in three different regimens: (1) gentamicin (150, 300 or 600 mg/kg) containing a constant 300:1 molar ratio of gentamicin:GTTR; (2) 300 mg/kg gentamicin containing a variable molar ratio of gentamicin:GTTR (150:1-600:1), or (3) an increasing dose of gentamicin (150-900 mg/kg), each dose containing 1.7 mg/kg GTTR. Three hours later, cochleae were fixed and examined by confocal microscopy. First, increasing doses of a constant molar ratio of gentamicin:GTTR, resulted in increasing intensities of GTTR fluorescence in hair cells and strial tissues. Second, a fixed gentamicin dose with increasing molar dilution of GTTR led to decreasing GTTR fluorescence in hair cells and strial tissues. Third, a fixed GTTR dose with increasing molar dilution by gentamicin led to decreased GTTR uptake in hair cells and marginal cells, but not intra-strial tissues and capillaries. Thus, only hair cell and marginal cell uptake of GTTR is competitively inhibited by gentamicin, suggesting that a regulatable barrier for gentamicin entry into endolymph exists at the interface between marginal cells, the intra-strial space and intermediate cells.

Original languageEnglish (US)
Pages (from-to)114-124
Number of pages11
JournalHearing Research
Volume235
Issue number1-2
DOIs
StatePublished - Jan 2008

Fingerprint

Stria Vascularis
Gentamicins
Cochlea
Fluorescence
Endolymph
Aminoglycosides
Confocal Microscopy

Keywords

  • Aminoglycosides
  • Blood-labyrinth barrier
  • Cochlea
  • Gentamicin
  • Hair cells
  • Ototoxicity
  • Stria vascularis

ASJC Scopus subject areas

  • Sensory Systems

Cite this

A systemic gentamicin pathway across the stria vascularis. / Dai, Chun Fu; Steyger, Peter.

In: Hearing Research, Vol. 235, No. 1-2, 01.2008, p. 114-124.

Research output: Contribution to journalArticle

Dai, Chun Fu ; Steyger, Peter. / A systemic gentamicin pathway across the stria vascularis. In: Hearing Research. 2008 ; Vol. 235, No. 1-2. pp. 114-124.
@article{c0db2738e5b94086864dcc97ce40ae2b,
title = "A systemic gentamicin pathway across the stria vascularis",
abstract = "The mechanism(s) by which systemically-administered aminoglycosides enter the cochlea remain poorly understood. To elucidate which mechanisms may be involved, we co-administered different molar ratios of gentamicin and fluorescent gentamicin (GTTR) to mice in three different regimens: (1) gentamicin (150, 300 or 600 mg/kg) containing a constant 300:1 molar ratio of gentamicin:GTTR; (2) 300 mg/kg gentamicin containing a variable molar ratio of gentamicin:GTTR (150:1-600:1), or (3) an increasing dose of gentamicin (150-900 mg/kg), each dose containing 1.7 mg/kg GTTR. Three hours later, cochleae were fixed and examined by confocal microscopy. First, increasing doses of a constant molar ratio of gentamicin:GTTR, resulted in increasing intensities of GTTR fluorescence in hair cells and strial tissues. Second, a fixed gentamicin dose with increasing molar dilution of GTTR led to decreasing GTTR fluorescence in hair cells and strial tissues. Third, a fixed GTTR dose with increasing molar dilution by gentamicin led to decreased GTTR uptake in hair cells and marginal cells, but not intra-strial tissues and capillaries. Thus, only hair cell and marginal cell uptake of GTTR is competitively inhibited by gentamicin, suggesting that a regulatable barrier for gentamicin entry into endolymph exists at the interface between marginal cells, the intra-strial space and intermediate cells.",
keywords = "Aminoglycosides, Blood-labyrinth barrier, Cochlea, Gentamicin, Hair cells, Ototoxicity, Stria vascularis",
author = "Dai, {Chun Fu} and Peter Steyger",
year = "2008",
month = "1",
doi = "10.1016/j.heares.2007.10.010",
language = "English (US)",
volume = "235",
pages = "114--124",
journal = "Hearing Research",
issn = "0378-5955",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - A systemic gentamicin pathway across the stria vascularis

AU - Dai, Chun Fu

AU - Steyger, Peter

PY - 2008/1

Y1 - 2008/1

N2 - The mechanism(s) by which systemically-administered aminoglycosides enter the cochlea remain poorly understood. To elucidate which mechanisms may be involved, we co-administered different molar ratios of gentamicin and fluorescent gentamicin (GTTR) to mice in three different regimens: (1) gentamicin (150, 300 or 600 mg/kg) containing a constant 300:1 molar ratio of gentamicin:GTTR; (2) 300 mg/kg gentamicin containing a variable molar ratio of gentamicin:GTTR (150:1-600:1), or (3) an increasing dose of gentamicin (150-900 mg/kg), each dose containing 1.7 mg/kg GTTR. Three hours later, cochleae were fixed and examined by confocal microscopy. First, increasing doses of a constant molar ratio of gentamicin:GTTR, resulted in increasing intensities of GTTR fluorescence in hair cells and strial tissues. Second, a fixed gentamicin dose with increasing molar dilution of GTTR led to decreasing GTTR fluorescence in hair cells and strial tissues. Third, a fixed GTTR dose with increasing molar dilution by gentamicin led to decreased GTTR uptake in hair cells and marginal cells, but not intra-strial tissues and capillaries. Thus, only hair cell and marginal cell uptake of GTTR is competitively inhibited by gentamicin, suggesting that a regulatable barrier for gentamicin entry into endolymph exists at the interface between marginal cells, the intra-strial space and intermediate cells.

AB - The mechanism(s) by which systemically-administered aminoglycosides enter the cochlea remain poorly understood. To elucidate which mechanisms may be involved, we co-administered different molar ratios of gentamicin and fluorescent gentamicin (GTTR) to mice in three different regimens: (1) gentamicin (150, 300 or 600 mg/kg) containing a constant 300:1 molar ratio of gentamicin:GTTR; (2) 300 mg/kg gentamicin containing a variable molar ratio of gentamicin:GTTR (150:1-600:1), or (3) an increasing dose of gentamicin (150-900 mg/kg), each dose containing 1.7 mg/kg GTTR. Three hours later, cochleae were fixed and examined by confocal microscopy. First, increasing doses of a constant molar ratio of gentamicin:GTTR, resulted in increasing intensities of GTTR fluorescence in hair cells and strial tissues. Second, a fixed gentamicin dose with increasing molar dilution of GTTR led to decreasing GTTR fluorescence in hair cells and strial tissues. Third, a fixed GTTR dose with increasing molar dilution by gentamicin led to decreased GTTR uptake in hair cells and marginal cells, but not intra-strial tissues and capillaries. Thus, only hair cell and marginal cell uptake of GTTR is competitively inhibited by gentamicin, suggesting that a regulatable barrier for gentamicin entry into endolymph exists at the interface between marginal cells, the intra-strial space and intermediate cells.

KW - Aminoglycosides

KW - Blood-labyrinth barrier

KW - Cochlea

KW - Gentamicin

KW - Hair cells

KW - Ototoxicity

KW - Stria vascularis

UR - http://www.scopus.com/inward/record.url?scp=37549053577&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37549053577&partnerID=8YFLogxK

U2 - 10.1016/j.heares.2007.10.010

DO - 10.1016/j.heares.2007.10.010

M3 - Article

C2 - 18082985

AN - SCOPUS:37549053577

VL - 235

SP - 114

EP - 124

JO - Hearing Research

JF - Hearing Research

SN - 0378-5955

IS - 1-2

ER -